Company intelligence / Profile preview

EndoCross

Ownership: Private
Development stage: Commercial

Overview

EndoCross has developed the ENABLER-C Catheter System, designed to facilitate crossing challenging lesions such as chronic total occlusions during percutaneous interventions. Early first-in-human studies demonstrated significant capability for crossing difficult lesions in blocked coronary arteries. The ENABLER 3C study was conducted at Institut Cardiovasculaire Paris-Sud under Dr. Yves Louvard and had enrolled one-third of planned patients by October 2013.

Therapeutic areas: Cardiovascular
Modalities: DeviceCatheter-based system
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on EndoCross.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoCross.

Explore the full profile